Abstract
Treatment options for patients with malignant pleural mesothelioma (MPM) include surgery, radiation therapy (RT), and/or chemotherapy. Multimodality treatment of MPM with surgery, radiation therapy, and adjuvant or neoadjuvant chemotherapy is the sole path to extended survival for select patients with favorable prognostic factors. If MPM is in a resectable stage (stage I–III), macroscopic complete resection (MCR) – realized as extrapleural pneumonectomy (EPP) or radical pleurectomy/decortication (P/D) – is the basic concept for surgical approach. MCR is the basic concept, and the technique chosen has to be tailored according to the patient’s performance status and wish, stage of disease in terms of possible MCR, and available combination modalities [1–3].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Rice D, Rusch V, Pass H, et al. Recommendations for uniform definitions of surgical techniques for malignant pleural mesothelioma: a consensus report of the International Association for the Study of Lung Cancer International Staging Committee and the International Mesothelioma Interest Group. J Thorac Oncol. 2011;6:1304–12.
Flores RM, Pass HI, Seshan VE, et al. Extrapleural pneumonectomy versus pleurectomy/decortication in the surgical management of malignant pleural mesothelioma: results in 663 patients. J Thorac Cardiovasc Surg. 2008;135:620–6.
Spaggiari L, Marulli G, Boyolato P, et al. Extrapleural pneumonectomy for malignant mesothelioma: an Italian multicenter retrospective study. Ann Thorac Surg. 2014;97:1859–65.
Flores RM, Riedel E, Donington JS, et al. Frequency of use and predictors of cancer-directed surgery in the management of malignant pleural mesothelioma in a community-based (Surveillance, Epidemiology, and End Results [SEER]) population. J Thorac Oncol. 2010;5:1649–54.
Treasure T, Lang-Lazdunski L, Waller D, et al. Extra-pleural pneumonectomy versus no extra-pleural pneumonectomy for patients with malignant pleural mesothelioma: clinical outcomes of the Mesothelioma and Radical Surgery (MARS) randomised feasibility study. Lancet Oncol. 2011;12:763–72.
Sugarbaker DJ, Gill RR, Yeap BY, Wolf AS, DaSilva MC, Baldini EH, et al. Hyperthermic intraoperative pleural cisplatin chemotherapy extend interval to recurrence and survival among low – risk patients with malignant pleural mesothelioma undergoing surgical macroscopic complete resection. J Thorac Cardiovasc Surg. 2013;145:955–63.
Sugarbaker DJ, Wolf AS, Chirieac LR, et al. Clinical and pathological features of three-year survivors of malignant pleural mesothelioma following extrapleural pneumonectomy. Eur J Cardiothorac Surg. 2011;40:298–303.
Lang-Lazdunski L. Surgery for malignant pleural mesothelioma: why, when and what? Lung Cancer. 2014;84:103–9.
Rusch VW, Giroux D. Do we need a revised staging system for malignant pleural mesothelioma? Analysis of the IASLC database. Ann Cardiothorac Surg. 2012;1:438–48.
Wilcox BE, Subramaniam RM, Peller PJ, et al. Utility of integrated computed tomography-positron emission tomography for selection of operable malignant pleural mesothelioma. Clin Lung Cancer. 2009;10:244–8.
Teh E, Fiorentino F, Tan C, Treasure T. A systematic review of lung-sparing extirpative surgery for pleural mesothelioma. J R Soc Med. 2011;104:69–80.
Cao C, Tian D, Park J, et al. A systematic review and meta-analysis of surgical treatments for malignant pleural mesothelioma. Lung Cancer. 2014;83:240–5.
Bovolato P, Casadio C, Bille A, et al. Does surgery improve survival of patients with malignant pleural mesothelioma? A multicenter retrospective analysis of 1365 consecutive patients. J Thorac Oncol. 2014;9:390–6.
Zauderer MG, Krug LM. The evolution of multimodality therapy for malignant pleural mesothelioma. Curr Treat Options Oncol. 2011;12:163–72.
Zahid I, Sharif S, Routledge T, Scarci M. Is pleurectomy and decortication superior to palliative care in the treatment of malignant pleural mesothelioma? Interact Cardiovasc Thorac Surg. 2011;12:812–7.
Rusch VW, Giroux D, Kennedy C, Ruffini E, Cangır AK, Rice D, Pass H, Asamura H, Waller, Edwards J, Weder W, van Meerbeeck HHJP, on behalf of the IASLC Staging Committee and participating institutions. Initial analysis of the International Association for the Study of Lung Cancer mesothelioma database. J Thorac Oncol. 2012;7:1631–9.
Pass HI, Giroux D, Kennedy C, Ruffini E, Cangır AK, Rice D, Asamura H, Waller D, Edwards J, Weder W, van Meerbeeck HHJP, Rusch VW, on behalf of the IASLC Staging Committee and Participating Institutions. Supplementary prognostic variables for pleural mesothelioma a report from the IASLC staging committee. J Thorac Oncol. 2014;9:856–64.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2016 Springer International Publishing Switzerland
About this chapter
Cite this chapter
Kahya, Y., Dikmen, E., Cangır, A.K. (2016). Modern Surgical Techniques in Malignant Pleural Mesothelioma. In: Ozyigit, G., Selek, U., Topkan, E. (eds) Principles and Practice of Radiotherapy Techniques in Thoracic Malignancies. Springer, Cham. https://doi.org/10.1007/978-3-319-28761-4_21
Download citation
DOI: https://doi.org/10.1007/978-3-319-28761-4_21
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-28759-1
Online ISBN: 978-3-319-28761-4
eBook Packages: MedicineMedicine (R0)